Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

Ensysce Biosciences (NASDAQ:ENSC) closed a second tranche of convertible preferred financing of $2.0 million on April 7, 2026, under a prior commitment providing up to $20 million over 24 months.

Rhea-AI Summary

Ensysce Biosciences (NASDAQ:ENSC) closed a second tranche of convertible preferred financing of $2.0 million on April 7, 2026, under a prior commitment providing up to $20 million over 24 months. The tranche has a $0.55 fixed conversion price and alternate conversion tied to average common prices.

The financing carries 100% warrant coverage with an 18-month term and an additional 100% warrant coverage with a five-year term, each exercisable at the fixed conversion price subject to adjustment. Proceeds will fund flagship abuse- and overdose-resistant analgesic programs and general corporate needs, alongside federal grant support for the MPAR program.

Positive

• Closed $2.0M convertible preferred financing
• Commitment of up to $20M available over 24 months
• Fixed conversion price at $0.55 per share
• 100% warrant coverage with 18-month and 5-year terms
• Financing directed to flagship analgesic programs and corporate needs

Negative

• Potential shareholder dilution from conversion and warrant coverage at $0.55
• Immediate $2.0M tranche may be limited versus full program funding needs

Argus Apr 7 session

+3.04% close to close Open Argus

Details

News Market Reaction – ENSC

In the Apr 7 session, ENSC gained 3.04%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds $2 million of convertible preferred financing from a larger $20 million commi...

Analysis

This announcement adds $2 million of convertible preferred financing from a larger $20 million commitment, supporting Ensysce’s late-stage pain programs and general operations. The structure includes a fixed $0.55 conversion price and layered warrant coverage, which can introduce dilution alongside balance sheet support. Recent history shows continued progression of PF614 and MPAR, a strategic review, and active investor outreach. Investors may watch execution on clinical milestones and any further capital draws under the agreement.

Key Figures

Current financing tranche: $2 million Total facility size: $20 million Funding window: 24 months +5 more

Current financing tranche

$2 million

Second convertible preferred stock financing under 2025 agreement

Total facility size

$20 million

Funding available over 24 months from November 2025 commitment

Funding window

24 months

Availability period for up to $20 million commitment

Fixed conversion price

$0.55 per share

Conversion price for the $2 million preferred tranche

Warrant coverage (short-term)

100% with 18-month term

Warrants exercisable at fixed conversion price, subject to adjustment

Warrant coverage (long-term)

100% with five-year term

Additional warrants exercisable at fixed conversion price

Pre-news share price

$0.5591

Price before article; about 88.47% below 52-week high

24h price change

-8.28%

Move prior to publication of financing announcement

Historical Context

5 past events · Latest: Mar 30

5 events

1. Mar 30

   Earnings and pipeline

   24h Move

   +4.8%

   Year-end 2025 results and PF614 Phase 3, PF614-MPAR progress update.

2. Mar 04

   Investor outreach AMA

   24h Move

   -1.0%

   Live AMA discussing PF614 growth plans and capital discipline.

3. Mar 03

   Clinical publication

   24h Move

   -15.0%

   Peer-reviewed Phase 1 data showing oral overdose protection for PF614-MPAR.

4. Feb 25

   Strategic review

   24h Move

   +1.1%

   Board launches review of strategic alternatives to enhance shareholder value.

5. Feb 23

   Conference participation

   24h Move

   -6.6%

   Announcements of multiple upcoming scientific and industry presentations.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

convertible preferred stock, conversion price, warrant coverage, warrants

4 terms

convertible preferred stock financial

"announced the closing of a second convertible preferred stock financing of $2 million"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

conversion price financial

"includes a fixed conversion price of $0.55 per share, with an alternate conversion price"

The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.

warrant coverage financial

"The financing includes 100% warrant coverage with an 18-month term and an additional 100%"

Warrant coverage is the share of a financing deal that comes with detachable warrants — coupons that let the holder buy company stock at a set price later. Investors get these as a sweetener for taking a risk, because warrants can turn into equity if the stock rises, while existing shareholders face potential dilution when those warrants are exercised.

warrants financial

"an additional 100% warrant coverage with a five-year term, each exercisable at the fixed"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~

SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the closing of a second convertible preferred stock financing of $2 million under prior commitment in November 2025 of up to $20 million funding available over 24 months.

The capital will maintain Ensysce's flagship analgesic programs, while supporting general corporate initiatives. The current $2 million tranche includes a fixed conversion price of $0.55 per share, with an alternate conversion price based upon average common stock prices prior to conversion. The financing includes 100% warrant coverage with an 18-month term and an additional 100% warrant coverage with a five-year term, each exercisable at the fixed conversion price, subject to adjustment.

Dr. Kirkpatrick, CEO of Ensysce Biosciences, stated, "This financing reflects continued investor confidence in Ensysce's differentiated analgesic programs, which we believe have the potential to reinvent pain management. Along with additional funds through our federal grant support for our MPAR program, we continue to advance the development of transformative treatments for patients in severe pain."

About Ensysce Biosciences

Ensysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP^TM) and Multi-Pill Abuse Resistance (MPAR^®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. Ensysce's pipeline is backed by a robust global intellectual property portfolio, offering hope to patients and providers confronting the challenges of pain management. Learn more at www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent annual report on Form 10-K and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences Inc.

View the original press release on ACCESS Newswire

FAQ

What financing did Ensysce (ENSC) close on April 7, 2026?

Ensysce closed a $2.0 million convertible preferred tranche on April 7, 2026. According to Ensysce, this draw is part of a prior commitment providing up to $20 million of funding available over 24 months to support programs and corporate needs.

What are the conversion terms for the ENSC April 2026 financing?

The tranche includes a fixed conversion price of $0.55 per share plus an alternate price based on average common prices. According to Ensysce, conversion mechanics allow adjustment and an alternate conversion price tied to pre-conversion average common stock prices.

How much warrant coverage came with Ensysce's April 2026 financing (ENSC)?

The financing includes 100% warrant coverage with an 18-month term and an additional 100% warrant coverage with a five-year term. According to Ensysce, each warrant is exercisable at the fixed conversion price, subject to standard adjustment terms.

How will the $2.0M ENSC financing be used by Ensysce?

Proceeds will fund Ensysce's flagship abuse- and overdose-resistant analgesic programs and general corporate initiatives. According to Ensysce, the tranche complements federal grant support for the MPAR program to advance development efforts.

Does Ensysce have additional funding available after the April 7, 2026 tranche?

Yes; the April 7, 2026 tranche is part of a commitment allowing up to $20 million over 24 months. According to Ensysce, additional tranches remain available under the prior financing agreement to support ongoing development and corporate needs.